In one study including 200 patients with chronic- and blast-phase MPNs, screening of IDH1 and IDH2 mutations determined that IDH mutations are relatively frequent in blast- but not chronic-phase MPN (21% and 4%, respectively). The gene discussed is IDH2; the disease is myeloproliferative neoplasm.